Foghorn Therapeutics (FHTX) Cash from Financing Activities (2019 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Cash from Financing Activities of $49.8 million for Q1 2026, up 35707.19% year-over-year from N/an in Q1 2025, and up 8466.61% quarter-over-quarter from $581000.0 in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $49.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 35707.19% year-over-year to $49.8 million; the TTM figure through Mar 2026 stood at $50.7 million (down 51.48% YoY), while the FY2025 annual figure was $1.0 million, down 99.03% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $49.8 million, up from $581000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $103.2 million in Q2 2024, with the low at $4000.0 in Q4 2024.
- The 5-year median for Cash from Financing Activities is $333000.0 (2022), against an average of $9.4 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 99.93% in 2022, then surged 100100.0% in 2024.
- Foghorn Therapeutics' Cash from Financing Activities stood at $16000.0 in 2022, then soared by 1062.5% to $186000.0 in 2023, then sank by 97.85% to $4000.0 in 2024, then surged by 14425.0% to $581000.0 in 2025, then surged by 8466.61% to $49.8 million in 2026.
- Business Quant data shows FHTX's Cash from Financing Activities at $49.8 million in Q1 2026, $581000.0 in Q4 2025, and $49000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Foghorn Therapeutics | 348.20 Mn | 280.12 Mn | - | -22,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22,000.00 |
| Mar 31, 2026 | 49.77 Mn |
| Dec 31, 2025 | 581,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 254,000.00 |
| Mar 31, 2025 | 139,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 103.21 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Dec 31, 2023 | 186,000.00 |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 103,000.00 |
| Mar 31, 2023 | 102,000.00 |
| Dec 31, 2022 | 16,000.00 |
| Sep 30, 2022 | 333,000.00 |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 384,000.00 |
| Dec 31, 2021 | 21.74 Mn |
| Sep 30, 2021 | 505,000.00 |